11,603 Shares in Astrazeneca Plc $AZN Acquired by Mattson Financial Services LLC

Mattson Financial Services LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 11,603 shares of the company’s stock, valued at approximately $2,036,000.

A number of other hedge funds also recently made changes to their positions in AZN. SmartHarvest Portfolios LLC purchased a new stake in shares of Astrazeneca during the 4th quarter valued at $751,000. Lyell Wealth Management LP purchased a new position in shares of Astrazeneca in the 4th quarter worth $484,000. Stirlingshire Investments Inc. acquired a new position in Astrazeneca in the fourth quarter valued at $542,000. CSM Advisors LLC grew its position in Astrazeneca by 21.9% during the fourth quarter. CSM Advisors LLC now owns 18,136 shares of the company’s stock valued at $3,183,000 after acquiring an additional 3,257 shares during the period. Finally, Picton Mahoney Asset Management purchased a new stake in Astrazeneca during the fourth quarter valued at about $495,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Tuesday. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research note on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Stock Performance

Shares of NYSE:AZN opened at $182.48 on Friday. The company has a market cap of $283.00 billion, a P/E ratio of 27.40, a PEG ratio of 1.56 and a beta of 0.25. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The business’s 50-day simple moving average is $189.75 and its 200 day simple moving average is $185.85.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The firm had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, sell-side analysts forecast that Astrazeneca Plc will post 9.37 earnings per share for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.